Open AccessAdvantages of the 99mTc-sestamibi single-photon emission computed tomography/computed tomography in occult parathyroid adenoma and concomitant thyroid papillary carcinoma
Author(s) -
Enrique CadenaPiñeros,
Cármen Amelia de los Reyes,
Augusto Llamas-Olier,
Alfredo RomeroRojas
Publication year - 2019
Publication title -
indian journal of nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 13
eISSN - 0972-3919
pISSN - 0974-0244
DOI - 10.4103/ijnm.ijnm_28_19
Subject(s) - medicine , radiology , parathyroid adenoma , occult , primary hyperparathyroidism , concomitant , thyroid carcinoma , hyperparathyroidism , parathyroid neoplasm , single photon emission computed tomography , technetium tc 99m sestamibi , parathyroid carcinoma , thyroidectomy , adenoma , emission computed tomography , nuclear medicine , thyroid , scintigraphy , pathology , positron emission tomography , surgery , alternative medicine
Hyperparathyroidism and concurrent thyroid nodular disease are prominent. In contrast, concomitant papillary thyroid cancer and hyperparathyroidism are uncommon (1%-2%). Parathyroid adenomas in unusual locations are difficult to detect by conventional diagnostic imaging. 99m Tc-sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) has increased the localizing success rate of these lesions since it provides specific functional and anatomical information, improving exploratory parathyroid surgery planning and decreasing operative time, unnecessary dissections, complications, and morbidity. We confirmed its usefulness in a patient with an occult parathyroid adenoma that was clearly identified by 99m Tc-sestamibi SPECT/CT 2 weeks after a thyroidectomy for papillary carcinoma. The SPECT/CT results allowed us to successfully perform efficient reexploration of the thyroid bed, in a retroesophageal parathyroid adenoma by minimally invasive surgery.